HitGen Inc. (SHA:688222)

Market Cap	10.98B +106.0%
Revenue (ttm)	579.37M +35.9%
Net Income	127.23M +93.7%
EPS	0.31 +79.5%
Shares Out	399.44M
PE Ratio	88.54
Forward PE	79.65
Dividend	0.06 (0.22%)
Ex-Dividend Date	n/a

Volume	36,581,285
Average Volume	19,435,300
Open	27.20
Previous Close	27.48
Day's Range	26.88 - 30.35
52-Week Range	14.96 - 42.98
Beta	0.58
RSI	51.63
Earnings Date	Apr 29, 2026

About HitGen

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company’s product pipeline also includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 492
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688222

Financial Performance

In 2025, HitGen's revenue was 525.57 million, an increase of 23.09% compared to the previous year's 426.99 million. Earnings were 114.02 million, an increase of 122.01%.